Parker Waichman LLP Headlines by Topic
Xigris
Xigris to be Recalled Worldwide
Oct 26, 2011
| Parker Waichman LLP
Xigris patients in a clinical trial did not experience any added survival benefit compared to those treated with placebo, prompting Eli Lilly to...
Xigris Linked to Increased Risk of Deaths, FDA Announces Safety Review
Feb 4, 2009
| Parker Waichman LLP
Xigris, a treatment for sepsis made by Eli Lilly, is now the subject of a Food & Drug Administration (FDA) safety review. The review was...
Page 1/1



